Comment
Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res., 9: 2040-2048, 2003
Affiliations
- PMID: 12796360
Item in Clipboard
Comment
Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res., 9: 2040-2048, 2003
Clin Cancer Res.
2003 Jun.
No abstract available
Comment on
-
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.Clin Cancer Res. 2003 Jun;9(6):2040-8. Clin Cancer Res. 2003. PMID: 12796366
Similar articles
-
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.Clin Cancer Res. 2003 Jun;9(6):2040-8. Clin Cancer Res. 2003. PMID: 12796366
-
Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale.Semin Oncol. 2003 Feb;30(1 Suppl 1):39-48. doi: 10.1053/sonc.2003.50031. Semin Oncol. 2003. PMID: 12644983
-
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.Semin Oncol. 2003 Feb;30(1 Suppl 1):30-8. doi: 10.1053/sonc.2003.50030. Semin Oncol. 2003. PMID: 12644982 Review.
-
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.J Clin Oncol. 2002 Nov 1;20(21):4292-302. doi: 10.1200/JCO.2002.03.100. J Clin Oncol. 2002. PMID: 12409327 Clinical Trial.
-
Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.Respir Med. 2005 Mar;99(3):298-307. doi: 10.1016/j.rmed.2004.08.009. Respir Med. 2005. PMID: 15733505 Review.
Cited by
-
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.J Transl Med. 2010 Feb 24;8:20. doi: 10.1186/1479-5876-8-20. J Transl Med. 2010. PMID: 20178647 Free PMC article. Clinical Trial.
-
A review of the application, feasibility, and the psychometric properties of the individualized measures in cancer.Qual Life Res. 2017 May;26(5):1091-1104. doi: 10.1007/s11136-016-1458-4. Epub 2016 Nov 18. Qual Life Res. 2017. PMID: 27864742 Review.
-
Chemotherapy research for metastatic prostate cancer.Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S140-S143. doi: 10.5489/cuaj.4055. Can Urol Assoc J. 2016. PMID: 27895810 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials